menu
    • menu
    [{"orgOrder":0,"company":"Ark Biosciences","sponsor":"Ark Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ziresovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ark Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ark Biosciences \/ Ark Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Ark Biosciences \/ Ark Biosciences"},{"orgOrder":0,"company":"Ark Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ziresovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ark Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ark Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ark Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ark Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AK3280","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ark Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ark Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ark Biosciences \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Ark Biosciences

    Menu

    Ark Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ark Biosciences

                            China arrow
                            AllPack Indonesia
                            Not Confirmed

                            Ark Biosciences

                            China arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AK3280

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ArkBio Shows Strong Phase II Results for AK3280 in Idiopathic Pulmonary Fibrosis

                            Details : AK3280 is a potential next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug. It is being evaluated for the treatment of Idiopathic Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 15, 2025

                            Lead Product(s) : AK3280

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ark Biosciences

                            China arrow
                            AllPack Indonesia
                            Not Confirmed

                            Ark Biosciences

                            China arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ziresovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ArkBio Announces Positive Results of Phase 3 Study with Ziresovir in Infants and Children Hospitalized with Re...

                            Details : Phase 3 AirFLO study with ziresovir, a novel small-molecule RSV fusion (F) protein inhibitor, met primary and key secondary endpoints of significant reduction of sign-and-symptom score (p=0.002) and viral load (p=0.006) respectively, compared with placeb...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 07, 2022

                            Lead Product(s) : Ziresovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ark Biosciences

                            China arrow
                            AllPack Indonesia
                            Not Confirmed

                            Ark Biosciences

                            China arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ziresovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Shanghai Ark Biopharmaceutical Co., Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Viral Inhibition in Children for Treatment of RSV

                            Details : AK0529 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Syncytial Virus Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 13, 2016

                            Lead Product(s) : Ziresovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Shanghai Ark Biopharmaceutical Co., Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth